share_log

Litchfield Hills Initiates Coverage On Mateon Therapeutics with Buy Rating, Announces Price Target of $3

Litchfield Hills Initiates Coverage On Mateon Therapeutics with Buy Rating, Announces Price Target of $3

利奇菲爾德山以購買評級啟動 Mateon 治療藥物的覆蓋範圍,宣布目標價格為 3 美元
Benzinga Real-time News ·  2020/12/07 20:25

Litchfield Hills initiates coverage on Mateon Therapeutics (OTC:MATN) with a Buy rating and announces Price Target of $3.

利奇菲爾德山啟動對馬特昂治療的覆蓋 (OTC:木馬恩)具有「買入」評級,並宣布目標價為 3 美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論